Information Provided By: 
Fly News Breaks for July 22, 2019
MRNS
Jul 22, 2019 | 08:02 EDT
Jefferies analyst Andrew Tsai believes Marinus Pharmaceuticals could rally 25%-50% on the two Phase II postpartum depression datasets, expected by the middle of August. With the stock at $4 per share, the risk/reward favors the upside as the market appears to ascribe a low 15%-25% probability for PPD, Tsai tells investors in a research note. The analyst adds that his "stronger conviction" for positive data is supported by prior datasets and his doctor checks. He keeps a Buy rating on Marinus with a $10 price target.
News For MRNS From the Last 2 Days
There are no results for your query MRNS
